# Palbociclib Plus Fulvestrant in Women With Hormone Receptor Positive and Human Epidermal Growth Factor Receptor Type 2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With a CDK4/6 Inhibitor in Combination With Hormonal Therapy

> **NCT04318223** · PHASE2 · UNKNOWN · sponsor: **Consorzio Oncotech** · enrollment: 168 (estimated)

## Conditions studied

- Metastatic Breast Cancer
- Locally Advanced Breast Cancer

## Interventions

- **DRUG:** Palbociclib

## Key facts

- **NCT ID:** NCT04318223
- **Lead sponsor:** Consorzio Oncotech
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-07-16
- **Primary completion:** 2023-07-31
- **Final completion:** 2023-07-31
- **Target enrollment:** 168 (ESTIMATED)
- **Last updated:** 2020-03-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04318223

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04318223, "Palbociclib Plus Fulvestrant in Women With Hormone Receptor Positive and Human Epidermal Growth Factor Receptor Type 2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With a CDK4/6 Inhibitor in Combination With Hormonal Therapy". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT04318223. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*